B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Cassava Sciences (SAVA - Research Report) today and set a price target of $44.00. The company's shares closed yesterday at $19.82.Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Arrowhead Pharmaceuticals, and Altimmune. According to TipRanks, Mamtani has an average return of -25.3% and a 25.57% success rate on recommended stocks. Cassava Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $69.00, implying a 248.13% upside from current levels. In a report released on August 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $124.00 price target.
https://www.tipranks.com/news/blurbs/b-riley-financial-keeps-their-buy-rating-on-cassava-sciences-sava-2?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Cassava Sciences Charts.